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PURPOSE. Thyrotropin receptor (TSHR) expression is upregu-
lated in the orbits of patients with Graves ophthalmopathy
(GO), most of whom have TSHR-stimulating antibodies. The
authors investigated the biological effects of TSHR activation in
vitro in adipose tissue, the site of orbital TSHR expression.
METHODS. Activating mutant TSHR (TSHR*) or wild-type (WT)
was introduced into human orbital preadipocytes using retro-
viral vectors. Their proliferation (Coulter counting), basal
cAMP accumulation (radioimmunoassay), and spontaneous
and peroxisome proliferator-activated receptor (PPAR)–in-
duced adipogenesis (quantitative oil red O staining) were as-
sessed and compared with those of nonmodified cells. QRT-
PCR was used to measure transcripts of CCAT/enhancer
binding protein (C/EBP), PPAR, and lipoprotein lipase (LPL;
early, intermediate, and late markers of adipogenesis) and for
uncoupling protein (UCP)-1 (brown adipose tissue [BAT]).
RESULTS. Expression of TSHR* significantly inhibited the pro-
liferation of preadipocytes and produced an increase in un-
stimulated cAMP of 200% to 600%. Basal lipid levels were
significantly increased in TSHR* (127%–275%) compared with
nonmodified (100%) or WT-expressing (104%–187%) cells.
This was accompanied by 2- to 10-fold increases in early-
intermediate markers and UCP-1 transcripts (2- to 8-fold); LPL
was at the limit of detection. In nonmodified cells, adipogen-
esis produced significant increases in transcripts of all markers,
including LPL (approximately 30-fold). This was not the case in
TSHR*-expressing cells, which also displayed 67% to 84% re-
ductions in lipid levels.
CONCLUSIONS. TSHR activation stimulates early differentiation
(favoring BAT formation?) but renders preadipocytes refractory
to PPAR-induced adipogenesis. In neither case did lipid-con-
taining vacuoles accumulate, suggesting that terminal stages of
differentiation were inhibited. (Invest Ophthalmol Vis Sci.
2006;47:5197–5203) DOI:10.1167/iovs.06-0596
Graves disease (GD) is caused by thyrotropin (TSH) recep-tor (TSHR)– stimulating antibodies (TSABs) that mimic the
action of TSH and produce hyperthyroidism.1 A proportion of
GD patients have ophthalmopathy (GO), in which expansion
of the orbital contents by adipogenesis, overproduction of
extracellular matrix, and edema lead to proptosis.2 The target
autoantigen of GD, the TSHR, is expressed in the orbits of GO
patients.3,4 Specifically, it is upregulated during adipogene-
sis.5,6 Recent improvements in patient management, especially
in avoiding elevated TSH levels, have decreased the incidence
of GO.7 Furthermore, a positive correlation has been reported
between TSAB titer and GO activity,8 as assessed using a
clinical activity score (CAS). These facts suggest that TSHR
activation (TSHR*), either by excess hormones or TSABs, con-
tribute to the disease process.
The receptor can also be activated by gain-of-function mu-
tations, with somatic changes responsible for toxic adenoma
and germline mutations causing familial hyperthyroidism.1 Of
interest, two newborns harboring different activating germline
TSHR mutations, L629F and M453T, displayed proptosis.9,10
We have exploited this activation mechanism to establish an in
vitro model to investigate the resultant biological effects, be-
ginning with adipose tissue, the site of TSHR expression in the
orbit.
METHODS
Sample Collection, Preadipocyte Culture,
Generation of TSHR*-Expressing Cells
Orbital adipose tissue was obtained with informed consent and rele-
vant local ethical approval. The research adhered to the tenets of the
Declaration of Helsinki.
Six tissue samples were collected, three from GO patients (under-
going decompression surgery) and three from patients free of GO and
thyroid autoimmunity (undergoing blepharoplasty with fat pad exci-
sion).
Preadipocytes were obtained from explants of the adipose tissues,
cultured in DMEM/F12 10% FCS (complete medium). Adipogenesis
was induced in confluent cells by replacement with medium having
reduced FCS and containing a range of hormones and PPAR agonists
(differentiation medium), for 10 days, as previously described.11
Activating mutant TSHR, L629F and M453T, and wild-type (WT)
were introduced using retroviral vectors previously produced in our
laboratory.12 Geneticin selection resulted in mixed populations stably
expressing the various TSHRs, all as previously described.12
Effect on Proliferation and cAMP Levels
WT, TSHR*-expressing, and nonmodified preadipocytes were plated at
5  104/well in 12-well plates. They were counted with a Coulter
particle counter 3 and 5 days after plating; the difference indicated
proliferation in 48 hours. Results were expressed as total increased cell
counts or as population doubling time (PDT).
The same plating conditions were used for cAMP estimates, but,
once attached, the cells were incubated for 4 hours in medium con-
taining 10–4 M isobutylmethylxanthine (IBMX) with no further addi-
tion (basal conditions) plus 10–5 M forskolin or 10 mU/mL bovine TSH.
Cyclic AMP was extracted in 0.1 M HCl and measured using an in-house
radioimmunoassay capable of detecting femtogram quantities of the
second messenger, as previously described.13 Coulter counting of
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adjacent wells provided an accurate cell number for results to be
expressed as picomole cAMP per 104 cells.
Effect on Spontaneous
and PPAR-Induced Adipogenesis
Various cell populations (in 12-well plates) were examined in com-
plete and differentiation medium. Microscopic examination provided a
means of determining whether morphologic changes, e.g., rounding
up of cells or acquisition of lipid-filled droplets, had occurred. In
addition, the cells were subjected to oil red O staining, followed by
extraction of the absorbed dye with 100% isopropanol and measure-
ment of the OD490. Coulter counting of adjacent wells provided an
accurate cell number for standardization of OD values.
QRT-PCR of Transcripts for Early, Intermediate,
and Late Adipogenesis and BAT
The various cell populations were plated in six-well plates in complete
or differentiation medium. Ten days later, RNA was extracted and
reverse transcribed, and transcript copy numbers for C/EBP, PPAR,
LPL, and UCP-1 were measured using Sybr green and a light cycler
(MX3000; Stratagene, La Jolla, CA). Primer details are provided in
Table 1.
Comparative analyses were performed with reference to the house-
keeping gene APRT. Results are expressed as fold differences in tran-
script copy number calculated from the ratio of crossing threshold (Ct)
value gene of interest: Ct value APRT.
Statistical Analysis
Means were compared nonparametrically by Kruskal-Wallis, post hoc
by Dunn’s multiple comparison test, and parametrically by ANOVA
with post hoc Tukey HSD.
RESULTS
Adipose Explants Can Be Maintained in Culture
for Long Periods
It was possible to harvest preadipocytes for up to 9 months,
during which time the explants shrank. Preadipocytes close to
the explant had oil red O–positive lipid-filled vacuoles (Fig. 1A)
that persisted. If the explants were detached from the culture
dish, lipid-filled vacuoles in the adherent preadipocytes de-
creased (Fig. 1B), whereas in dishes in which the explant was
completely removed, all cells assumed a uniform fibroblast
appearance (Fig. 1C). Cells from this last condition were used
for subsequent experimentation.
TSHR Activation Increases Intracellular
cAMP in Preadipocytes
In thyroid cells, the TSHR is coupled to Gs, which activates
adenylate cyclase and produces increased cAMP on ligand
binding or in the absence of ligand for gain-of-function mutants
such as M453T and L629F.1 To investigate whether the TSHR is
functional and similarly coupled in preadipocytes, we mea-
sured TSH-induced cAMP, whereas unstimulated cAMP levels
would indicate whether the gain-of-function mutants were
active. Forskolin provided a positive control and in all cases
induced a robust increase in cAMP corresponding to at least a
10-fold increase compared with basal.
As shown in Figures 2A and 2B, the nonmodified cells
responded minimally (twofold increase) to TSH, in keeping
with the very low proportion of these cells expressing the
receptor. In contrast, TSH induced a 4- to 16-fold increase in
cells expressing the WT or mutant forms of TSHR, indicating
that the receptor was coupled to Gs in these cells. Further-
more, unstimulated (basal) cAMP was significantly (P  0.05,
GO; P  0.01 non-GO) increased in the L629F- and M453T-
expressing cells compared with the nonmodified or WT, indi-
cating that the gain-of-function mutants were active in preadi-
pocytes from normal orbits and patients with GO.
TSHR Activation Inhibits
Preadipocyte Proliferation
The effects of TSHR activation on proliferation were studied. In
all cases proliferation was significantly inhibited when compar-
ing cells expressing the mutant TSHR and the nonmodified
cells, and in some instances between the WT and nonmodified
cells (representative examples are shown in Figs. 3A and 3B).
Effects were always most apparent with mutant M453T. In two
instances (1 GO, 1 non-GO) these cells proliferated so slowly
that insufficient numbers of cells were obtained for experimen-
tation.
GO and non-GO preadipocytes displayed inhibited prolifer-
ation that resulted in a significant increase in PDT (hours) from,
TABLE 1. Forward and Reverse Primer Sequences, Exon Locations, and Amplicon Sizes for Genes
Analyzed by QRT-PCR
Gene bp
Forward Reverse
Primer Exon Primer Exon
C/EBP 304 AACTTTGGCACTGGGG 1 GGCCCGGCTGACAGTT 1
PPAR 390 CAGTGGGGATGTCTCATA 3 CTTTTGGCATACTCTGTGAT 5
LPL 275 GAGATTTCTCTGTATGGACC 7 CTGCAAATGAGACACTTTCTC 9
UCP-1 540 CGGATGAAACTCTACAGCGG 2 CACTTTTGTACTGTCCTGGTGG 5
APRT 247 GCTGCGTGCTCATCCGAAAG 3 CTTTAAGCGAGGTCAGCTGC 5
FIGURE 1. Lipid-filled vacuoles in
preadipocytes close to adipose tissue
explant (A), in cultures in which the
explant was detached (B), and in cul-
tures in which the explant had been
removed from the dish (C).
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for example, 38 2.8 (nonmodified) to 43 4 (WT), 86 7.7
(L629F), and 160  15.2 (M453T) in preadipocytes from a
non-GO orbit.
TSHR Activation Induces Morphologic
Changes in Preadipocytes
In complete medium, orbital preadipocytes expressing mutant
TSHR had a more rounded appearance than their WT-express-
ing or nonmodified counterparts, but no obvious lipid vacuoles
were observed, either microscopically or after oil red O stain-
ing. A representative example is shown in Figure 4.
TSHR Activation Increases the Lipid
Content of Preadipocytes
Visual examination of the various preadipocyte populations
cultured in complete medium revealed no obvious oil red
O–staining droplets. However, when quantifying the lipid con-
tent, the mutant (and, to a lesser extent, WT) TSHR–express-
ing cells, from GO and non-GO orbits, displayed increased oil
red O staining compared with nonmodified cells (P  0.05,
GO; P  0.01, non-GO), as illustrated in representative exam-
ples in Figure 5.
To mimic more closely the situation in GD, the various
preadipocyte populations were cultured in complete medium
supplemented with T3 (1 nM). Because insulin is reported to
be essential for adipogenesis, experiments were also per-
formed in complete medium supplemented with insulin (500
nM) alone or combined with T3. Neither set of conditions
resulted in the appearance of lipid vacuoles, nor was there any
further increase in the lipid content of the cells, assessed using
oil red O. A representative example is shown in Figure 6.
TSHR Activation Renders Preadipocytes
Refractory to PPAR-Induced Adipogenesis
The various preadipocyte populations were allowed to reach
confluence and then were maintained in differentiation me-
dium for 10 days. In the nonmodified cells, morphologic evi-
dence of differentiation and visible oil red O–stained droplets
FIGURE 2. cAMP levels in nonmodi-
fied or WT/activating mutant TSHR
(L629F, M453T) expressing preadi-
pocytes from patients with GO (A)
and non-GO (B) orbits. Results are
expressed as picomoles cAMP per
104 cells measured in basal condi-
tions or in response to 10 mU/mL
TSH or 10–5 M forskolin.
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were apparent in all microscopic fields examined and was
accompanied by a significant increase in lipid content. The
behavior of the preadipocytes transduced with the WT recep-
tor was similar to the equivalent nonmodified population. In
contrast, in cells expressing the most potent activating mutant,
TSHR oil red O–stained vacuoles were absent, and there was
little or no increase in the lipid content. A representative
example (non-GO preadipocytes) is shown in Figure 6. Repre-
sentative examples (GO preadipocytes) of the morphologic
changes and oil red O–stained vacuoles are shown in Figure 7.
TSHR Activation Induces Early and Intermediate
Markers of Adipogenesis
Results obtained with oil red O staining of the mutant-express-
ing preadipocytes were paradoxical. Microscopic examination
revealed no positive vacuoles in complete medium and re-
duced or no vacuoles in differentiation medium, yet the basal
lipid content of the cells was higher but failed to increase in
response to a PPAR agonist. To investigate further, the tran-
script copy number of genes whose expression is upregulated
during adipogenesis was calculated.
In nonmodified preadipocytes, PPAR-induced adipogene-
sis (visible oil red O–positive lipid droplets) was accompanied
by an increase in all the markers of differentiation tested
FIGURE 3. Proliferation (increase in
cell number in 48 hours) in nonmodi-
fied or WT/activating mutant (L629F,
M453T) TSHR–expressing preadipo-
cytes from patients with Graves oph-
thalmopathy (GO) (A) and non-GO
orbits (B) cultured in complete me-
dium.
FIGURE 4. Nonmodified preadipocytes from a non-GO orbit appear as
elongated fibroblasts. The same cells expressing mutant TSHR L629F
have a more rounded appearance (non-GO 629).
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compared with the equivalent transcript copy number ob-
tained in these cells in complete medium.
In the TSHR*-expressing cells, no PPAR-induced adipogen-
esis was apparent, and the transcript copy number of the
differentiation markers was not increased. In fact, in some
instances it was reduced compared with the same cells in
complete medium.
When comparing the nonmodified cells and the TSHR*-
expressing cells, all in complete medium, transcript copy num-
bers for markers of early to intermediate differentiation and
brown adipose tissue formation, but not those for the terminal
stages of adipogenesis, were upregulated, as summarized in
Table 2. A representative example of the individual Ct values
obtained is shown in Table 3.
DISCUSSION
Orbital fat is a scarce commodity, compounded by the loss of
phenotype of preadipocytes that have undergone several pas-
sages. We modified explant cultures, transferred the adipose
tissue fragments to new dishes for reattachment, and thus were
able to harvest first-passage preadipocytes for several months.
A heterogeneous population of cells migrates from the ex-
plants, including fibroblast-like preadipocytes and cells at var-
ious stages of fat maturation. Cells containing lipid vacuoles
could be fibroblast-like preadipocytes undergoing adipogenesis
or cells at various stages of fat maturation in the process of
de-differentiating. Gesta et al.14 have indicated that de-differ-
entiation occurs within the first 48 hours of culture. We ob-
served cells close to the explants with lipid-filled droplets that
persisted for several months. Only detachment or removal of
the explant reduced the lipid droplets, indicating the produc-
tion of pro-adipogenic signals, both soluble and through cell–
cell contact, by mature fat.
Our subsequent experiments indicated that TSHR activation
stimulates the early stages of adipogenesis but inhibits the
terminal stages of differentiation. The absence of lipid-filled
droplets, combined with increased cellular lipid content, sug-
gests that lipolysis is upregulated or that the cytoskeletal
changes necessary for droplet formation have been inhibited.
FIGURE 5. Lipid accumulation, ex-
pressed as OD490 of oil red O stain-
ing, in nonmodified or WT/activating
mutant (L629F, M453T) TSHR–ex-
pressing preadipocytes from patients
with GO and non-GO orbits cultured
in complete medium.
FIGURE 6. Lipid accumulation, ex-
pressed as OD490 of oil red O stain-
ing, in nonmodified or WT/activating
mutant TSHR (L629F, M453T) ex-
pressing preadipocytes from a
non-GO orbit cultured in complete
medium alone or supplemented with
T3 plus insulin (T3/Ins) or in differ-
entiation medium (Diff).
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The fact that lipoprotein lipase transcripts remain at the limit
of detection in cells expressing TSHR* favors the latter mech-
anism. The results agree with earlier reports of cAMP elevation
rapidly reducing a suppressor of adipogenesis, Wnt,15 thereby
promoting differentiation. In contrast, prolonged elevation of
cAMP by pharmacologic agents reduced the accumulation of
lipids by decreasing key lipogenic enzymes rather than increas-
ing lipolysis.16
TSHR activation also seems to favor the development of
brown adipose tissue. Although elevated UCP-1 transcripts are
a feature of human preadipocytes exposed to PPAR ago-
nists,17 we observed an increase in UCP-1 copies in the TSHR*-
expressing cells, even in complete medium (basal conditions).
It is possible that this feature may be restricted to orbital
preadipocytes, a depot having many similarities with brown
adipose tissue such as selective expansion (along with intras-
capular fat) in mice overexpressing adiponectin.18
We opted to use gain-of-function mutants of the TSHR as an
activation mechanism rather than adding the pathologic li-
gands TSAB. At the time this study began, only patient sera
containing heterogeneous mixes of TSAB were available be-
cause monoclonal TSABs have only recently been devel-
oped.19–22 Furthermore, our previous experiences demon-
strated that the vectors transduced a physiological level of
TSHR expression because we were unable to distinguish en-
dogenous rat TSHR from transduced human TSHR using flow
cytometry in a rat thyroid cell line.12 The model also has the
advantage of generating free  and / subunits of the G
protein, unlike an earlier study23 in which constitutively active
Gs mutants were expressed in the murine 3T3L1 cell line
There was no effect on proliferation; basal cAMP or rates of
adipogenesis compared with nonmodified cells were not ex-
amined.
Recent studies have reported that the activation of CREB
(by phosphorylation) is necessary and sufficient to induce
adipogenesis in the 3T3L1 preadipocyte cell line.24 CREB can
be activated by the cAMP/PKA route, though there are other
activation mechanisms. In the FRTL5 thyroid cell line, we
observed increased phosphorylated CREB (p-CREB) in cells
expressing TSHR* compared with the WT or nonmodified
cells.25 Thus, we expected that the human preadipocytes ex-
pressing the same gain-of-function mutant TSHR would also
have increased p-CREB and should thus have exhibited spon-
taneous adipogenesis. However preliminary experiments indi-
cate that this is not the case, with threefold to fourfold higher
levels of pCREB present in WT compared with activating mu-
tant TSHR-expressing cells. This is in agreement with the work
of Brunetti et al.,26 who demonstrated increased adenylate
cyclase but reduced pCREB in toxic adenoma (somatic TSHR*)
compared with adjacent healthy thyroid tissue. We assume that
the discrepancy between cAMP and pCREB is the consequence
of upregulation of counterregulatory mechanisms—e.g., the
inducible cAMP early repressor27—induced by the higher lev-
els of cAMP present in the L629F- and M453T-transduced prea-
dipocytes. The difference illustrates that though they provide
useful in vitro models, rodent preadipocyte cell lines do not
replicate all aspects of human adipogenesis.
Although we have investigated primary preadipocytes, our
model does not faithfully reproduce TSHR expression during
adipogenesis. Haraguchi et al.28 demonstrated that the recep-
tor is upregulated and reaches a maximum at around day 9 of
an adipogenesis protocol, including insulin, dexamethasone,
and a phosphodiesterase inhibitor. Transcript levels then de-
clined. Our vectors are driven by a viral promoter so that
receptor expression is permanently “ON. ” We are generating
inducible retroviral vectors and siRNA to permit the modula-
tion of activating TSHR expression and to mimic more closely
that occurring during adipogenesis.
Apart from this shortcoming, our model has addressed how
TSHR activation might affect just one of the mechanisms op-
erating to increase the orbital volume in GO. We are aware that
not all GO patients have circulating TSABs and that other
processes may be in operation. Furthermore, the TSHR is
expressed on only a small proportion of orbital fibroblasts.
Increased cAMP in preadipocytes has been associated with
the production of an adipogenic factor, a putative endogenous
PPAR agonist.29 If this were the case, TSHR activation could
have an indirect effect on adipogenesis by elaborating an adi-
pogenic factor having paracrine effects. Experiments are under
way using conditioned media from our transduced cells to
investigate their proadipogenic activity on primary preadipo-
cytes from various fat depots, including the orbit.
In conclusion, we have demonstrated that TSHR activation
stimulates early differentiation and may favor the formation of
brown adipose tissue. In contrast, TSHR activation renders
preadipocytes refractory to PPAR-induced adipogenesis. In
neither case do lipid-containing vacuoles accumulate, suggest-
ing that terminal stages of differentiation have been inhibited.
TABLE 2. Fold Increases
Fold Change in TCN PPAR vs. Basal Medium
Fold Change TCN Basal
TSHR* vs. NonmodifiedNonmodified Cells TSHR* Expressing
C/EBP 1.5–5  increase 2–3  reduction 2–10  increase
PPAR 7–20  increase 0–4  increase 2–4  increase
LPL 20–30  increase Limit of detection Limit of detection
UCP-1 10–150  increase 0–7  increase 2–8  increase
Nonmodified and WT-activating mutant TSHR (L629F, M453T)–expressing preadipocytes from GO
and non-GO orbits cultured in complete medium or in differentiation medium. TCN, transcript copy
number; C/EBP, CAACT enhancer-binding protein beta; PPAR, peroxisome proliferator activated recep-
tor gamma; LPL, lipoprotein lipase; UCP-1, uncoupling protein 1.
FIGURE 7. Oil red O staining in WT or activating mutant TSHR M453T
expressing preadipocytes from a patient with GO in differentiation
medium.
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TABLE 3. Crossing Threshold Values Obtained in Preadipocytes from a Donor Free of GO and
Maintained in Complete Medium or in Differentiation Medium
Ct
Complete Medium PPAR-Induced Adipogenesis
APRT PPAR APRT PPAR
Non-Go 26.5  0.2 30.3  0.6 25  0.3 25.2  0.5
WT 26  0.1 29  0.2 26.6  0.7 29.1  0.8
L629F 25.4  0.3 27  0.6 24.3  0.4 26  0.4
M453T 26  0.5 28  0.5 25  0.2 26  0.6
Values are expressed as mean  SD. Each experiment was performed in triplicate (these agreed to
within 10%), and all were repeated at least twice. Thus, crossing threshold (Ct) values quoted are the mean
of at least six measurements.
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